Mechanisms of Ivermectin-induced Wound Healing
Overview
Affiliations
Background: Wounds cause structural and functional discontinuity of an organ. Wound healing, therefore, seeks to re-establish the normal morphology and functionality through intertwined stages of hemostasis, inflammation, proliferation, and tissue remodelling. Ivermectin, a macrolide, has been used as an endectoparasiticide in human and veterinary medicine practice for decades. Here, we show that ivermectin exhibits wounding healing activity by mechanisms independent of its well-known antiparasitic activity. This study aimed to evaluate the wound healing property of ivermectin cream using histochemistry and enzyme-linked immunosorbent assay techniques.
Results: Non-irritant dose of ivermectin cream (0.03-1%) decreased wound macroscopic indices such as exudation, edge edema, hyperemia, and granulation tissue deposition by day 9 compared to day 13 for the vehicle-treated group. This corresponded with a statistically significant wound contraction rate, hydroxyproline deposition, and a decreased time to heal rate. The levels of growth factors TGF-β1 and VEGF were significantly elevated on day 7 but decreased on day 21. This corresponded with changes in cytokines (IL-1α, IL-4, IL-10, and TNF-α) and eicosanoids (LTB4, PGE, and PGD) levels on days 7 and 21. Interestingly, low doses of ivermectin cream (0.03-0.1%) induced wound healing with minimal scarring compared to higher doses of the cream and the positive control, Silver Sulfadiazine.
Conclusion: Ivermectin promotes wound healing partly through modulation of the inflammatory process and the levels of Transforming Growth Factor-Beta 1 and Vascular Endothelial Growth Factor. Low doses of ivermectin cream have the potential to be used in treating wounds with minimal scar tissue formation.
Neuroprotective effects of ivermectin against transient cerebral ischemia-reperfusion in rats.
Seyyedabadi B, Babataheri S, Laher I, Soraya H Metab Brain Dis. 2023; 38(8):2807-2815.
PMID: 37755672 DOI: 10.1007/s11011-023-01290-8.
Suppression of NLRP3 inflammasome by ivermectin ameliorates bleomycin-induced pulmonary fibrosis.
Abd-Elmawla M, Ghaiad H, Gad E, Ahmed K, Abdelmonem M J Zhejiang Univ Sci B. 2023; 24(8):723-733.
PMID: 37551558 PMC: 10423969. DOI: 10.1631/jzus.B2200385.
A Lead Target Molecule for Excisional Wound Healing: Trypthantrin Compound.
Kutlu Z, Halici Z, Gedikli S, Diyarbakir B, Civelek M Iran J Pharm Res. 2023; 21(1):e127665.
PMID: 36945339 PMC: 10024809. DOI: 10.5812/ijpr-127665.
Ivermectin: A Controversial Focal Point during the COVID-19 Pandemic.
Castillejos-Lopez M, Torres-Espindola L, Huerta-Cruz J, Flores-Soto E, Romero-Martinez B, Velazquez-Cruz R Life (Basel). 2022; 12(9).
PMID: 36143420 PMC: 9502658. DOI: 10.3390/life12091384.
Chowdhury A, Sajid M, Jahan N, Adelusi T, Maitra P, Yin G Biomed Pharmacother. 2021; 142:111956.
PMID: 34332377 PMC: 8313489. DOI: 10.1016/j.biopha.2021.111956.